Bleeding post coronary artery bypass surgery. Clopidogrel--cure or culprit?

Area of Science:

• Cardiology
• Cardiovascular Surgery
• Pharmacology

Background:

• Clopidogrel is commonly used with aspirin for acute coronary syndrome and stent thrombosis prevention.
• Preoperative clopidogrel use poses a bleeding risk in patients undergoing coronary artery bypass grafting (CABG).

Purpose of the Study:

• To evaluate the impact of preoperative clopidogrel use on bleeding complications after CABG.

Main Methods:

• Retrospective cohort study of 462 patients undergoing CABG.
• Comparison between patients who took clopidogrel within 7 days of surgery (n=162) and those who did not (n=300).
• Primary outcomes included chest tube output and bleeding index.

Main Results:

• Patients taking clopidogrel within 7 days of CABG had higher bleeding index and chest tube output.
• Immediate exposure (clopidogrel within 3 days of CABG) showed significantly higher bleeding index and major bleeding compared to recent exposure (3-7 days) or no exposure.
• Chest tube output was also significantly higher in the immediate exposure group.

Conclusions:

• Preoperative clopidogrel use within three days of CABG increases the risk of post-operative bleeding.
• Discontinuing clopidogrel more than three days prior to CABG may reduce bleeding complications.